M
Maribel Rodriguez-Torres
Researcher at San Juan Bautista School of Medicine
Publications - 138
Citations - 13678
Maribel Rodriguez-Torres is an academic researcher from San Juan Bautista School of Medicine. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 44, co-authored 137 publications receiving 13171 citations. Previous affiliations of Maribel Rodriguez-Torres include Consejo Nacional de Ciencia y Tecnología & Pontifical Catholic University of Puerto Rico.
Papers
More filters
Journal ArticleDOI
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection
Andrew J. Muir,Sanjeev Arora,Gregory T. Everson,Robert Flisiak,Jacob George,Reem Ghalib,Stuart C. Gordon,T. Gray,Susan Greenbloom,Tarek Hassanein,J. Hillson,Maria Arantxa Horga,Ira M. Jacobson,Lennox J. Jeffers,Kris V. Kowdley,Eric Lawitz,Stefan Lueth,Maribel Rodriguez-Torres,Vinod K. Rustgi,Lynn Shemanski,Mitchell L. Shiffman,Subasree Srinivasan,Hugo E. Vargas,John M. Vierling,Dong Xu,Juan Carlos Lopez-Talavera,Stefan Zeuzem +26 more
TL;DR: Lambda was associated with improved or similar rates of virologic response with fewer extrahepatic adverse events than alfa in chronic HCV infection in patients chronically infected with HCV genotypes 1-4.
Journal ArticleDOI
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
Christophe Hézode,Gideon M. Hirschfield,Wayne Ghesquiere,William Sievert,Maribel Rodriguez-Torres,Stephen D. Shafran,Paul J. Thuluvath,Harvey A Tatum,Imam Waked,Gamal Esmat,Eric Lawitz,Vinod K. Rustgi,Stanislas Pol,Nina Weis,Paul J. Pockros,Marc Bourlière,Lawrence Serfaty,John M. Vierling,Michael W. Fried,Ola Weiland,Maurizia Rossana Brunetto,Gregory T. Everson,Stefan Zeuzem,Paul Y. Kwo,Mark S. Sulkowski,Norbert Bräu,Dennis Hernandez,Fiona McPhee,Megan Wind-Rotolo,Zhaohui Liu,Stephanie Noviello,Eric Hughes,Philip D. Yin,Steven Schnittman +33 more
TL;DR: A majority of daclatasvir-treated patients achieved PDR and experienced less virologic failure and higher SVR24 rates with a shortened 24-week treatment duration, which was generally well tolerated and achieved higher Svr24 rates compared with placebo/peginterferon-alfa/ribavirin among patients infected with HCV genotype 1 or 4.
Journal ArticleDOI
Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients With HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy
Nezam H. Afdhal,Geoffrey Dusheiko,Edoardo G. Giannini,Pei-Jer Chen,Kwang Hyub Han,Aftab Mohsin,Maribel Rodriguez-Torres,Sorin Rugină,Igor G. Bakulin,E.J. Lawitz,Mitchell L. Shiffman,Ghias Un Nabi Tayyab,Fred Poordad,Yasser Mostafa Kamel,Andres Brainsky,James Geib,Sandra Y. Vasey,Rita Patwardhan,Fiona Campbell,Dickens Theodore +19 more
TL;DR: Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV and advanced fibrosis and cirrhosis, allowing otherwise ineligible or marginal patients to begin and maintain antiviral therapy, leading to significantly increased rates of SVR.
Journal Article
svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3
Ira M. Jacobson,Reem Ghalib,Maribel Rodriguez-Torres,Zobair M. Younossi,Ana Corregidor,Mark S. Sulkowski,Edwin DeJesus,Brian L. Pearlman,Mordechai Rabinovitz,Norman Gitlin,Joseph K. Lim,Paul J. Pockros,Bart Fevery,Tom Lambrecht,Sivi Ouwerkerk-Mahadevan,Katleen Callewaert,William T. Symonds,Gaston Picchio,Karen L. Lindsay,M. Beumont-Mauviel,Eric Lawitz +20 more
Journal ArticleDOI
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis†
Paul J. Pockros,Lennox J. Jeffers,Nezam H. Afdhal,Zachary Goodman,David R. Nelson,Robert G. Gish,K. Rajender Reddy,Robert Reindollar,Maribel Rodriguez-Torres,Sarah Sullivan,Lawrence M. Blatt,Sima Faris-Young +11 more
TL;DR: Interferon‐γ1b therapy was not able to reverse fibrosis in patients with advanced liver disease for 1 year, and subgroups of patients with elevated ITAC levels and perhaps less advanced disease may be considered for future studies with IFN‐γ 1b.